Automation Opportunities in Pharmacovigilance: An Industry Survey

Abstract

Background TransCelerate's Intelligent Automation Opportunities (IAO) in Pharmacovigilance initiative has been working to evaluate various pharmacovigilance processes to facilitate systematic innovation with intelligent automation across the entire area. The individual case safety report (ICSR) process was the first process selected for evaluation because of its resource-intensive nature, risk of errors, and operational inefficiencies. Objectives TransCelerate's IAO in Pharmacovigilance initiative initially worked to articulate an end-to-end ICSR process that would generically apply to various pharmacovigilance organizations, despite organizational variations in specific ICSR process steps. This paper aims to address the need for a systematic review framework for automation of the ICSR process from the value, impact, perceived risk, and opportunity point of view. Methods The generic ICSR process, which starts with receipt of an adverse event report, was grouped into three process blocks: case intake, case processing, and case reporting. Each of these was then further detailed in individual process steps. A total of 19 TransCelerate member companies were invited to complete a survey designed to facilitate understanding of automation opportunities across the ICSR process. Heat maps of the current level of effort, expected benefit of automation, and perceived risk of automation were compiled from responses to identify intelligent automation opportunities for specific ICSR process steps. Relevant experts on the TransCelerate evaluation team analyzed and interpreted the anonymized and aggregated results. Results In total, 15 TransCelerate member companies responded to the survey and indicated that ICSR process steps with current high effort, expected high automation benefit, low or manageable automation risk, and low levels of current automation present the best opportunities for future automation. Such steps include language translations, case verification, in-line quality control, prioritization/triage, data entry, alerts for cases of interest, workflow management, and monitoring. Some steps (e.g., submission) have been automated for a number of years and appear on the heat map as having low potential for further automation. The survey responses implied that, despite successful use of intelligent automation technologies in other areas, adoption within pharmacovigilance and the ICSR process in particular remains limited. The perceived high risk to patient safety is expected to decrease with additional successful applications in pharmacovigilance. Conclusions Our results highlight the areas of greatest opportunity for intelligent automation based on the potential benefits of applying intelligent automation and the perceived risks associated with each ICSR process step. Responding TransCelerate member companies already automate many steps to varying degrees. However, a significant opportunity remains for automation to penetrate further. Additionally, the pharmacovigilance industry culture needs to change in order to re...

Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant?

“…For instance, from development to pharmacovigilance, Machine Learning could be used for data mining or to automate current processes. Indeed, the literature mentions that machine learning is used to automate pharmacovigilance processes [ 31 ]. This automation could improve both the detection of safety signals and risk management [ 31 ].…”

“…Indeed, the literature mentions that machine learning is used to automate pharmacovigilance processes [ 31 ]. This automation could improve both the detection of safety signals and risk management [ 31 ]. In addition, machine learning can also be used to identify relationships between biological terms [ 32 ] from medical records or social media screening and extract adverse event data [ 33 ] as illustrated with the Word2Vec algorithm [ 33 ].The latter application is related to the identification of adverse events using syntactical relationships between words [ 33 ].…”

Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices

“…More recently, novel areas of research based on artificial intelligence (AI) technologies have evolved, including machine learning (ML) and natural language processing (NLP) techniques, and are now being adopted to support pharmacovigilance processes [8][9][10]. Although these types of technology show great promise with their capability to learn based on data inputs, existing validation frameworks may need to be augmented to verify intelligent automation systems.…”

“…The primary focus of this paper is validation rather than other adoption considerations and potential barriers to implementation. This paper considers the use of intelligent automation solutions for pharmacovigilance, specifically for high-effort activities such as ICSR case processing [ 10 ]. The principles proposed may be applied to different areas that are subject to regulatory oversight.…”

Safety of medicines and vaccines – building next generation capability

“…Since the early days of pharmacovigilance, the international reach of spontaneous reporting has increased [47], along with the number of organisations expecting copies of such reports. The original recipient of an ICSR, in addition to managing and acting on the report, has also legislative obligations to share the ICSR with multiple partners (e.g., other companies or regulators) [48]. In this context, for example, unidentified duplicate copies of ICSRs can readily propagate and hinder effectiveness of the system [49] (Box 2).…”